Sunflower Pharmaceuticals Group Co Ltd Total Assets
Sunflower Pharmaceuticals Group Co Ltd total assets. Based on the latest financial reports, Sunflower Pharmaceuticals Group Co Ltd (002737) holds total assets worth CN¥5.36 Billion CNY (≈ $783.70 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Sunflower Pharmaceuticals Group Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Sunflower Pharmaceuticals Group Co Ltd (2011–2025)
Total assets of Sunflower Pharmaceuticals Group Co Ltd from 2011 to 2025. This chart illustrates how Sunflower Pharmaceuticals Group Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002737 share price today for real-time trading data and today's change.
Sunflower Pharmaceuticals Group Co Ltd - Asset Composition Analysis
Sunflower Pharmaceuticals Group Co Ltd Total Assets Breakdown (December 2025)
Sunflower Pharmaceuticals Group Co Ltd total assets breakdown as of December 2025. Sunflower Pharmaceuticals Group Co Ltd's total assets of CN¥5.36 Billion consist of 65.7% current assets and 34.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.0% |
| Accounts Receivable | CN¥62.15 Million | 1.2% |
| Inventory | CN¥617.43 Million | 11.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥312.73 Million | 5.9% |
| Goodwill | CN¥56.44 Million | 1.1% |
Asset Composition Trend (2011–2025)
This chart illustrates how Sunflower Pharmaceuticals Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sunflower Pharmaceuticals Group Co Ltd (002737) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sunflower Pharmaceuticals Group Co Ltd's current assets represent 65.7% of total assets in 2025, an increase from 51.5% in 2011.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2025, down from 21.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 12.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 11.6% of total assets.
Sunflower Pharmaceuticals Group Co Ltd Competitors by Total Assets
Key competitors of Sunflower Pharmaceuticals Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Sunflower Pharmaceuticals Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 4.15 | 2.23 |
| Quick Ratio | 2.72 | 3.31 | 1.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.49 Billion | CN¥2.95 Billion | CN¥1.80 Billion |
Sunflower Pharmaceuticals Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sunflower Pharmaceuticals Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -8.5% |
| Total Assets | CN¥5.33 Billion |
| Market Capitalization | $1.03 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sunflower Pharmaceuticals Group Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sunflower Pharmaceuticals Group Co Ltd's assets decreased by 8.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sunflower Pharmaceuticals Group Co Ltd (2011–2025)
The table below shows the annual total assets of Sunflower Pharmaceuticals Group Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.33 Billion ≈ $779.70 Million |
-8.54% |
| 2024-12-31 | CN¥5.83 Billion ≈ $852.51 Million |
-15.35% |
| 2023-12-31 | CN¥6.88 Billion ≈ $1.01 Billion |
-2.13% |
| 2022-12-31 | CN¥7.03 Billion ≈ $1.03 Billion |
+24.78% |
| 2021-12-31 | CN¥5.64 Billion ≈ $824.61 Million |
+10.21% |
| 2020-12-31 | CN¥5.11 Billion ≈ $748.24 Million |
-3.69% |
| 2019-12-31 | CN¥5.31 Billion ≈ $776.92 Million |
+4.94% |
| 2018-12-31 | CN¥5.06 Billion ≈ $740.31 Million |
+13.18% |
| 2017-12-31 | CN¥4.47 Billion ≈ $654.13 Million |
+5.84% |
| 2016-12-31 | CN¥4.22 Billion ≈ $618.05 Million |
+12.19% |
| 2015-12-31 | CN¥3.76 Billion ≈ $550.88 Million |
+0.85% |
| 2014-12-31 | CN¥3.73 Billion ≈ $546.26 Million |
+77.88% |
| 2013-12-31 | CN¥2.10 Billion ≈ $307.09 Million |
+10.78% |
| 2012-12-31 | CN¥1.89 Billion ≈ $277.22 Million |
+21.67% |
| 2011-12-31 | CN¥1.56 Billion ≈ $227.85 Million |
-- |
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines in China and internationally. It offers traditional Chinese medicines, chemical drugs, biological drugs, and health and wellness products, as well as adult and children's medicines for various therapeutic areas, including pediatrics, gynecology,… Read more